Institutional Biosafety Committee (IBC)
- Animal Research
- Biohazards and Lab Safety
- Clinical Trial Billing
- Conflict of Interest
- Core Research Services
- Grants and Funding
- Intellectual Property
- Links to Research Programs
- News + Events
- Quick Links
- Institutional Biosafety Committee (IBC)
- Responsible Conduct of Research
- Research Protection Office
- Research Administration Training
Request Biostatistician Consult (requires Lifespan network password)
Effective April 2, 2018, the Biohazards and Laboratory Safety Committee has been combined with the Recombinant DNA Committee. The new committee is called the Lifespan Institutional Biosafety Committee and will review all proposals for the use of biological hazards, chemical hazards, and recombinant and synthetic nucleic acids.
The Institutional Biosafety Committee (IBC) is composed of scientists and community members who review all research proposals involving recombinant and synthetic nucleic acids, chemical hazards, and biological hazards. The review process ensures that experiments are performed with appropriate safety precautions, and that all laboratory personnel are trained in the proper handling and disposal of hazardous agents.
Research with recombinant DNA must conform to specific guidelines set out by the US National Institutes of Health (NIH). In the context of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, recombinant and synthetic nucleic acids are defined as: (i) molecules that a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids; (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or (iii) molecules that result from the replication of those described in (i) or (ii) above.
Chemical and Biological Hazards:
For the purposes of IBC review, hazardous agents are defined as:
- Chemical and biological agents that have been assigned a safety rating of 4 or greater in any category on the (SDS) Safety Data Sheet.
- Any compound listed as a carcinogen, mutagen or teratogen in the Chemical Hygiene Plan.
- Any toxin including such proteins as ricin, cholera toxin and bacterial toxins.
- Any organism included in the list of Risk Group 2 (RG2) or higher or organisms in appendix B of the NIH Guidelines or organisms that require Biosafety Level Containment Level 2 (BSL2) or higher as defined by the Centers for Disease Control (CDC) manual Biosafety in Microbiological and Biomedical Laboratories (BMBL). Please note that at this time Rhode Island Hospital does not have the facilities to handle Biosafety Level Containment Level 3 or 4.
- Use of human source cells/tissue or any hazardous organism or chemical that will be administered to live animals as per IACUC protocol.
Recombinant DNA Committee
Chairperson: Cynthia Jackson, PhD, 401-444-4370
Vice Chairperson: Loren Fast, PhD, 401-444-8091
Associate Chairperson: JiSu Li, MD, PhD, 401-444-2939
Associate Chairperson: Jennifer Sanders, PhD, 401-444-5802
Manager: Jacqueline Poore, 401-444-5483
Coordinator: Kate Brilliant, 401-444-2093
For information, please call 401-444-2093.
Send all correspondence to Coro West, Suite 1.300.